

Bill No. CS for CS for SB 370

Amendment No. ____ Barcode 742614

1 forms provided by the department. This section does not apply
2 to:

3 (a) Pharmacists employed by pharmacies that
4 participate in the program provided by Rule 64B16-27.300,
5 Florida Administrative Code; or

6 (b) Pharmacists employed by pharmacies that have
7 notified the Board of Pharmacy that they will establish a
8 continuous quality-improvement program consistent with the
9 requirements of Rule 64B16-27.300, Florida Administrative
10 Code.

11 (4) The required notification to the department must
12 be submitted in writing by certified mail and postmarked
13 within 15 days after the pharmacist or health care
14 practitioner became aware of the patient's allegation that a
15 pharmaceutical adverse incident has occurred.

16 (5) Effective July 1, 2004, subject to subsequent act
17 of the Legislature and a specific appropriation sufficient to
18 cover the actual costs, the department shall review each
19 incident and determine whether it potentially involved conduct
20 by a pharmacist or health care practitioner who is subject to
21 disciplinary action, in which case section 465.073, Florida
22 Statutes, applies. Disciplinary action, if any, shall be
23 taken by the board under which the pharmacist or health care
24 practitioner is licensed.

25 (6) The Department of Health shall adopt forms and
26 rules for administering this section.

27 Section 43. Section 42 of this act shall take effect
28 only upon the effective date of legislation that makes any
29 such information provided to the Department of Health
30 confidential and exempt from section 119.07(1), Florida
31 Statutes, and Section 24(a) of Article I of the State

Bill No. CS for CS for SB 370

Amendment No. ____ Barcode 742614

1 Constitution, until 10 days after probable cause is found that
2 a violation of law occurred. Such legislation must also
3 provide that information may be used by the department or the
4 Board of Pharmacy only in a disciplinary proceeding brought
5 against the pharmacist or by the department in any study of
6 adverse incidents without identifying the patient, pharmacist,
7 pharmacy, office, or entity by name, location, or other
8 identifier.

9
10 (Redesignate subsequent sections.)

11
12

13 ===== T I T L E A M E N D M E N T =====

14 And the title is amended as follows:

15 On page 4, line 5, after the semicolon

16

17 insert:

18 creating the "Ernest Belles Act"; defining the
19 term "pharmaceutical adverse incident" and
20 requiring that such incidents be reported to
21 the Department of Health; providing exceptions;
22 requiring the department to review reported
23 incidents to determine whether the incidents
24 potentially involve conduct by a health care
25 practitioner that is subject to disciplinary
26 action; specifying that any disciplinary action
27 shall be taken by the appropriate board;
28 providing for the adoption of rules and forms;

29
30
31